Global Cystic Fibrosis Treatment Market Report and Forecast 2024-2032

Global Cystic Fibrosis Treatment Market Outlook

The global market value in 2023 was USD 9.41 billion, driven by the increasing prevalence of the disease and the introduction of new therapies across the globe. The global cystic fibrosis market size is anticipated to grow at a CAGR of 13.4% during the forecast period of 2024-2032 to achieve a value of USD 29.19 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cystic Fibrosis Insights

Cystic fibrosis (CF) is an inherited disease that causes severe damage to the lungs, digestive system, and other body organs. Cystic fibrosis affects the cells responsible for the production of mucus, sweat, and digestive juices. Normally, these secreted fluids are thin and slippery, however, in people with cystic fibrosis, a faulty gene causes the secretions to become sticky and thick.  These secretions, rather than acting as lubricants, clog tubes, ducts, and passageways, particularly in the lungs and pancreas. 

Despite the fact that cystic fibrosis is a progressive disease that necessitates daily care, people with CF are usually able to do all the daily activities. Patients suffering from CF now have a better quality of life than previous generations of CF patients. Due to the advancements in screening and treatment, people with CF can now live in their mid- to late-30s or 40s, with some even living into their 50s. 

The signs and symptoms in the respiratory and digestive systems include:

• A chronic cough that produces thick mucus (sputum)

• Wheezing

• Intolerance to Exercise

• Recurring Lung Infections

• Inflammation of the Nasal Passages or a Stuffy Nose

• Sinusitis that Recurs

The thick mucus can also obstruct the tubes that transport digestive enzymes from the pancreas to the small intestine. Without these digestive enzymes, the intestines are unable to absorb all of the nutrients in the food consumed. It often results in:

• Smelly and Greasy Stools

• Inadequate Weight Gain and Growth

• Intestinal Obstruction, especially in New-Borns

• Constipation that is chronic or severe, with frequent straining to pass stool, eventually causing part of the rectum to protrude outside the anus.

CF is caused by a mutation in the "cystic fibrosis transmembrane conductance regulator" gene, or CFTR gene. Gene regulates the movement of water and salt into and out of the cells. A sudden mutation or change in the CFTR gene causes the mucus to thicken and stickier than usual. This abnormal mucus raises the salt content of the sweat and accumulates in various organs throughout the body, including the intestines, pancreas, liver, and lungs.

According to the cystic fibrosis treatment market research report, the market can be categorized into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Treatment Method

• Drug Treatment

• Airway Clearance Technique

• Pulmonary Rehabilitation

• Surgical Methods
  • Nasal and Sinus Surgery
  • Bowel Surgery
  • Lung Transplant
  • Liver Transplant
• Others

Market Breakup by Drug Class

• Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

• Bronchodilators

• Mucolytics

• Pancreatic Enzyme Supplement

• Others

Market Breakup by Route of Administration

• Oral Drug

• Inhaled Drug

Market Breakup by Distribution Channel

• Hospital Based Pharmacies

• Online Pharmacies

• Retail Pharmacies

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cystic Fibrosis Therapeutic Landscape

According to the Cystic Fibrosis Foundation, over 30,000 people in the United States have cystic fibrosis, and an additional 1,000 are diagnosed each year. Since CF is a progressive disease, it worsens over time and thus the treatment is extremely crucial. 

Although there is no cure for CF, there are several treatments that can help relieve the symptoms and reduce the risk of complications. The available treatments include antibiotics, mucus-thinning medication, NSAIDs, Bronchodilators, CFTR, whereas the surgical procedures include bowel surgery, feeding tube, and double lung transplant. Other than medications and surgical treatment, chest physical therapy and home care are also included in the management of this disease.

Drivers and Constraints

The market growth has been aided by an increase in the number of cystic fibrosis patients worldwide. Cystic fibrosis pharmacotherapy has resulted in a number of advancements in the treatment of this ailment, which is positively impacting the market growth. 

Cystic fibrosis treatment market growth is expected to be driven by the rise in non-profit initiatives, increase in government-backed legislation, and increases in research and development funding.  Researchers are expected to increase their investment in research and development activities in order to fuel market growth. There are a number of drugs in development, including Symdeko, VX-561, ELX-02, and ABBV-3067.

In terms of region, the global market is expected to be dominated by North America. The dominance can be attributed to the rapid increase in cystic fibrosis cases in the region, an increase in patients with various respiratory diseases affecting cystic fibrosis, and higher healthcare costs. 

Europe is in the second position, following North America in terms of demand for advanced drugs due to the prevalence of the disease and the increased use of advanced drugs to achieve better results. 

On the other hand, there are some factors which have been restricting the growth of the market. Along with the positive effects these medicines provide, there are some side effects that come with these medicines. These undesirable side effects include upper respiratory tract infections, liver problems, chest pain, and an increase in blood pressure, among other issues, and may obstruct the growth of the treatment market.

Clinical Trial

In the past few years, it has been observed that patients with cystic fibrosis have been able to live longer due to the rapid improvements in clinical care. There are some European countries where life expectancy has increased to 30-40 years. 

The growth of the cystic fibrosis treatment market is driven by the treatment of lung diseases and improved nutrition. The current treatment strategies can be improved by identifying new effective agents. Various clinical trials are underway for several drugs that are suspected of being effective in combating CFTR dysfunction. Cystic fibrosis is a condition that affects many organs. 

The development of drugs to treat lung disease, dyspepsia, and pancreatic malabsorption has become increasingly important. Researchers are developing drugs in many fields, including anti-inflammatory treatments, ion channel blockers, and genetic therapies. 

A major objective of pancreatic insufficiency treatment is to develop pancreatic enzymes that work most efficiently. A variety of treatments for cystic fibrosis are driving the growth of the cystic fibrosis treatment market. 

• Treatment with nebulized antibiotics for chronic lung disease reduces lung damage and improves lung function.

• There is a reduction in exacerbations and improved quality of life in a randomized controlled trial of azithromycin FEV1 treatment.

• The use of Ursodeoxycholic acid (URSO) in patients has been shown to normalize liver enzyme levels.

• Several clinical trials have been conducted to restore CFTR function in patients suffering from disease. Transient and moderate effects of gene transfer were observed on CFTR function. There have been improvements to gene transfer agents and plasmids, and clinical trials will commence shortly.

The cystic fibrosis treatment market is experiencing rapid growth due to an increasing demand for research.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global cystic fibrosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• Genentech, Inc.

• Gilead Sciences, Inc.

• Novartis International AG

• Vertex Pharmaceuticals Incorporated

• Johnson & Johnson Services, Inc

• Allergan Plc.

• Nestle Health Science S.A.

• AbbVie Inc.

• Horizon Therapeutics Plc.

• Chiesi Farmaceutici S.P.A.

• Pharmaxis Ltd.

• Teva Pharmaceuticals Industries Ltd

Key Highlights of the Report

Cystic Fibrosis Treatment Market Report Snapshots

Cystic Fibrosis Treatment Market Size

Cystic Fibrosis Treatment Market Growth

Cystic Fibrosis Treatment Companies